4 active not recruiting, 4 recruiting, 1 terminated. 6 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Active not recruiting 2, Terminated 1 |
| Phase 3 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Intismeran Autogene: new trials by email Literature Review of Intismeran Autogene trials Research Report on Intismeran Autogene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) Intismeran Autogene, Pembrolizumab, Carboplatin - Squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 180 | 2025-12-12 | 2026-10-01 |
| A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) Intismeran autogene, Pembrolizumab, Placebo - Malignant Melanoma | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2025-05-29 | 2026-09-28 |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) Intismeran autogene, BCG - Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 308 | 2025-03-11 | 2026-10-01 |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Pembrolizumab, Cisplatin, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 680 | 2024-10-21 | 2026-10-16 |
| A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) Pembrolizumab, Intismeran autogene, Surgery - Carcinoma, Squamous Cell, Skin Neoplasms | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 46 | 2024-04-18 | 2026-05-08 |
| A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). Intismeran autogene, Pembrolizumab, Placebo - Renal Cell Carcinoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 272 | 2024-04-10 | 2026-07-13 |
| A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) Pembrolizumab, Intismeran autogene, Placebo - Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 230 | 2024-03-28 | 2026-01-13 |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) Intismeran autogene, Pembrolizumab, Placebo - Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 868 | 2023-12-06 | 2026-09-18 |
| A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Intismeran autogene, Pembrolizumab, Placebo - Melanoma | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 1089 | 2023-07-19 | 2025-09-24 |
Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Urinary Bladder Neoplasms (2) · Carcinoma in Situ (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Skin Neoplasms (1)
Australia (9) · France (9) · Italy (9) · Poland (9) · Spain (9) · United States (9) · Canada (8) · Chile (8) · Germany (8) · Argentina (7) · New Zealand (6) · South Korea (6) · Turkey (Türkiye) (6) · United Kingdom (6) · Brazil (5)
2023 (7), 2025 (1)